Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 79 Carcinoma, Renal Cell 36 Neoplasms 35 Liver Neoplasms 22 Carcinoma, Non-Small-Cell Lung 7 Carcinoma 7 Neoplasm Metastasis 6 Melanoma 5 Thyroid Neoplasms 4 Kidney Neoplasms 4 Breast Neoplasms 3 Financial Stress 2 Vaccinia 1 Stomach Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoma 1 Lung Neoplasms 1 Liver Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulin-Like Growth Factor I, Resistance To 1 Hypophosphatemia 1 Hepatitis C 1 Hepatitis B 1 Glioblastoma 1 Digestive System Neoplasms 1

Interventions

Nivolumab 19 Ipilimumab 9 linrodostat 6 relatlimab 4 Pemetrexed 4 Paclitaxel 4 Carboplatin 4 ARRY-334543 4 Docetaxel 3 regorafenib 2 anlotinib 2 abemaciclib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Gemcitabine 2 Cyclophosphamide 2 Capecitabine 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 trametinib 1 tislelizumab 1 sargramostim 1 ralimetinib 1 prexasertib 1 palifosfamide lysine 1 p38 Mitogen-Activated Protein Kinases 1 mirdametinib 1 lirilumab 1 indibulin 1 gedatolisib 1 fluzoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Cancer × Sorafenib × Clear all

NCT00785226 2016-10-17

RDEA119 and Sorafenib Combination Dose Escalation Study

Bayer

Phase 1/2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡